The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic.
Read More
Pruritus continues to be a significant comorbidity in patients with chronic cholestatic liver diseases and may be exacerbated by certain bile acid-related drugs.
Read More
The company’s cannabinoid-based mouthwash and toothpaste, were included in registration for clinical trials through the Australian and New Zealand Clinical Trial Registry.
Read More
The company has received an export permit from Health Canada for the shipment of cannabis solid concentrate.
Read More![CURE Pharmaceutical [OTCQB:CURR] and Canopy Growth to Produce CBD Oral Thin Films](https://www.investinweed.com/wp-content/uploads/Cure-Pharmaceutical-627x376.png)
This CUREfilm license gives Canopy a dosage form that is ideal for administering cannabinoids.
Read More
Get stock alerts, news & related alerts straight to your inbox!